MWG
KALV

Martin Worley Group’s KalVista Pharmaceuticals KALV Stock Holding History

Martin Worley Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$115K Hold
10,168
– – 0.06% 90
2025
Q1 		$117K Hold
10,168
– – 0.07% 81
2024
Q4 		$86.1K Buy
+10,168
New +$105K 0.05% 85

Other funds holding KALV

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Martin Worley Group's KALV Position: Q2 2025 in Review

Martin Worley Group held its KalVista Pharmaceuticals (KALV) position steady in Q2 2025 at 10,168 shares worth $115K. The position accounts for 0.06% of the portfolio, ranked #90.

Martin Worley Group first reported a position in KALV in Q4 2024 and has held it in 3 quarters since. The position peaked at $117K in Q1 2025. 139 funds tracked by Wall St. Rank hold KALV as of Q2 2025.

  • Martin Worley Group held 10,168 shares of KalVista Pharmaceuticals worth $115K as of Q2 2025.
  • Martin Worley Group left its KalVista Pharmaceuticals share count unchanged in Q2 2025.
  • KalVista Pharmaceuticals made up 0.06% of Martin Worley Group's portfolio in Q2 2025, its #90 holding.
  • Martin Worley Group first reported a position in KalVista Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • Martin Worley Group's KalVista Pharmaceuticals position peaked at $117K in Q1 2025.
  • 139 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2025.

Based on Martin Worley Group's 13F filing for Q2 2025, filed 12 Aug 2025.